The Hi's and Lo's of Cytarabine in Acute Myeloid Leukemia

Justin M. Watts, Terrence Bradley

Research output: Contribution to journalComment/debatepeer-review

Abstract

Cytarabine is the backbone of AML therapy, but the dose used during induction has remained controversial. Using an intermediate dose of cytarabine, compared with conventional dose, was shown to improve disease-free and overall survival in adult patients in China up to age 55, particularly in patients with intermediate cytogenetic risk.See related article by Wei et al., p. 3154.

Original languageEnglish (US)
Pages (from-to)3073-3076
Number of pages4
JournalClinical cancer research : an official journal of the American Association for Cancer Research
Volume26
Issue number13
DOIs
StatePublished - Jul 1 2020

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'The Hi's and Lo's of Cytarabine in Acute Myeloid Leukemia'. Together they form a unique fingerprint.

Cite this